Skip to Main Content

APAL2020D: Venetoclax in Children with Relapsed Acute Myeloid Leukemia

About this study

This study will test treatments for acute myeloid leukemia (AML) that has come back (relapsed). The study will test whether adding a new medicine called venetoclax to chemotherapy will improve survival for children with this disease.

Half of the patients in this study will get venetoclax along with typical chemotherapy. The other half will get typical chemotherapy alone. A computer, rather than your doctor, will choose which treatment you receive.

Eligibility overview

  • At least 29 days old and up to 21 years old
  • Have had AML come back for the first or second time
  • May have heart problems that prevent them from taking anthracyclines

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.


Full title:

A Randomized Phase 3 Trial of Fludarabine/ Cytarabine/ Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Study goal:

To find out if adding venetoclax to standard chemotherapy leads to improved survival for children and young adults with relapsed AML.


29 days old to 21 years old

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.


Learn more